Genotyping-guided approach versus the conventional approach in selection of oral P2Y12 receptor blockers in Chinese patients suffering from acute coronary syndrome. (February 2017)

• Record Type: Journal Article
• Authors: Tam, Chor Cheung; Kwok, Janette; Wong, Anthony; Yung, Arthur; Shea, Catherine; Kong, Shun Ling; Tang, Wing Hong; Siu, David; Chan, Raymond; Lee, Stephen
• Is Part Of: Journal of international medical research. Volume 45:Number 1(2017)
• Page Start: 134
• Page End: 146
• Publication Date: 2017-02
• Subjects: P2Y12 receptor -- CYP2C19 -- acute coronary syndrome; Medicine -- Periodicals; Pharmacology -- Periodicals; 610.5
• DOI: 10.1177/0300060516677190
• Languages: English
• ISSNs: 0300-0605

Abstract

Objective: The CYP2C19 loss-of-function (LoF) allele is present in half of the East Asian population and is associated with high on-treatment platelet reactivity (HTPR). This study aimed to investigate whether a rapid genotyping-guided approach is feasible and efficacious for selecting P2Y12 receptor blockers in Chinese patients suffering from acute coronary syndrome (ACS). Methods: This was a single-centre, prospective, randomized, open-label study. A total of 132 patients with ACS were randomized to the rapid genotyping-guided treatment group (GG, N = 65) or the standard treatment group (SG, N = 67). Patients in the GG group were genotyped by the Verigene system. Patients with the CYP2C19 LoF allele were switched to ticagrelor and all remaining patients continued on clopidogrel. The endpoints were HTPR at 24 hours after the first loading dose of clopidogrel and 1 month afterwards. Results: Forty patients in the GG group switched to ticagrelor, while others continued on clopidogrel. The incidence of HTPR in the GG vs SG groups was 9.2% vs 40.3% at 24 hours and 6.5% vs 32.3% at 1 month, respectively. Rapid point-of-care genotyping showed 100% concordance with conventional genotyping by real-time polymerase chain reaction. Conclusions: In Chinese patients suffering from ACS, the rapid genotyping-guided approach for selecting P2Y12 receptor blockers is feasible and reduces the incidence of HTPR. Clinical Trial Registration: URL:http://clinicaltrials.gov . Unique identifier: NCT01994941.